|
1
|
Meriggioli MN and Sanders DB: Autoimmune
myasthenia gravis: Emerging clinical and biological heterogeneity.
Lancet Neurol. 8:475–490. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Juel VC and Massey JM: Myasthenia gravis.
Orphanet J Rare Dis. 2:442007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zisimopoulou P, Evangelakou P, Tzartos J,
Lazaridis K, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F,
Evoli A, Deymeer F, et al: A comprehensive analysis of the
epidemiology and clinical characteristics of anti-LRP4 in
myasthenia gravis. J Autoimmun. 52:139–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yeh JH, Chen HJ, Chen YK, Chiu HC and Kao
CH: Increased risk of osteoporosis in patients with myasthenia
gravis: A population-based cohort study. Neurology. 83:1075–1079.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cheng Z, Qiu S, Jiang L, Zhang A, Bao W,
Liu P and Liu J: MiR-320a is downregulated in patients with
myasthenia gravis and modulates inflammatory cytokines production
by targeting mitogen-activated protein kinase 1. J Clin Immunol.
33:567–576. 2013. View Article : Google Scholar
|
|
6
|
Lu J, Yan M, Wang Y, Zhang J, Yang H, Tian
FF, Zhou W, Zhang N and Li J: Altered expression of miR-146a in
myasthenia gravis. Neurosci Lett. 555:85–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y, Guo M, Xin N, Shao Z, Zhang X,
Zhang Y, Chen J, Zheng S, Fu L, Wang Y, et al: Decreased microRNA
miR-181c expression in peripheral blood mononuclear cells
correlates with elevated serum levels of IL-7 and IL-17 in patients
with myasthenia gravis. Clin Exp Med. 16:413–421. 2016. View Article : Google Scholar
|
|
8
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang YZ, Tian FF, Yan M, Zhang JM, Liu Q,
Lu JY, Zhou WB, Yang H and Li J: Delivery of an miR155 inhibitor by
anti-CD20 single-chain antibody into B cells reduces the
acetylcholine receptor-specific autoantibodies and ameliorates
experimental autoimmune myasthenia gravis. Clin Exp Immunol.
176:207–221. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ashburn TT and Thor KB: Drug
repositioning: Identifying and developing new uses for existing
drugs. Nat Rev Drug Discov. 3:673–683. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hu G and Agarwal P: Human disease-drug
network based on genomic expression profiles. PLoS One.
4:e65362009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meng F, Dai E, Yu X, Zhang Y, Chen X, Liu
X, Wang S, Wang L and Jiang W: Constructing and characterizing a
bioactive small molecule and microRNA association network for
Alzheimer's disease. J R Soc Interface. 11:201310572013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ye H, Yang LL, Cao ZW, Tang KL and Li YX:
A pathway profile-based method for drug repositioning. Chin Sci
Bull. 57:2106–2112. 2012. View Article : Google Scholar
|
|
14
|
Kim JY, Park KD and Richman DP: Treatment
of myasthenia gravis based on its immunopathogenesis. J Clin
Neurol. 7:173–183. 2011. View Article : Google Scholar
|
|
15
|
Lewis RA: Myasthenia gravis: New
therapeutic approaches based on pathophysiology. J Neurol Sci.
333:93–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang L, Wang J, Sun X, Cao Y, Ning S,
Zhang H, Chen L, Li R, Tian Q, Wang L, et al: Identifying a
polymorphic 'switch' that influences miRNAs' regulation of a
myasthenia gravis risk pathway. PLoS One. 9:e1048272014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Becker KG, Barnes KC, Bright TJ and Wang
SA: The genetic association database. Nat Genet. 36:431–432. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Piñero J, Queralt-Rosinach N, Bravo À,
Deu-Pons J, Bauer-Mehren A, Baron M, Sanz F and Furlong LI:
DisGeNET: a discovery platform for the dynamical exploration of
human diseases and their genes. Database (Oxford). 2015. pp.
bav0282015, View Article : Google Scholar
|
|
19
|
McKusick VA: Mendelian inheritance in man
and its online version, OMIM. Am J Hum Genet. 80:588–604. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schriml LM, Arze C, Nadendla S, Chang YW,
Mazaitis M, Felix V, Feng G and Kibbe WA: Disease Ontology: A
backbone for disease semantic integration. Nucleic Acids Res.
40:D940–D946. 2012. View Article : Google Scholar :
|
|
21
|
Li Y, Qiu C, Tu J, Geng B, Yang J, Jiang T
and Cui Q: HMDD v2.0: A database for experimentally supported human
microRNA and disease associations. Nucleic Acids Res.
42:D1070–D1074. 2014. View Article : Google Scholar :
|
|
22
|
Ruepp A, Kowarsch A, Schmidl D, Buggenthin
F, Brauner B, Dunger I, Fobo G, Frishman G, Montrone C and Theis
FJ: PhenomiR: A knowledgebase for microRNA expression in diseases
and biological processes. Genome Biol. 11:R62010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk - database: Prediction of possible miRNA binding sites by
'walking' the genes of three genomes. J Biomed Inform. 44:839–847.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hsu SD, Tseng YT, Shrestha S, Lin YL,
Khaleel A, Chou CH, Chu CF, Huang HY, Lin CM, Ho SY, et al:
miRTarBase update 2014: An information resource for experimentally
validated miRNA-target interactions. Nucleic Acids Res. 42:D78–D85.
2014. View Article : Google Scholar :
|
|
25
|
Jiang Q, Wang Y, Hao Y, Juan L, Teng M,
Zhang X, Li M, Wang G and Liu Y: miR2Disease: A manually curated
database for microRNA deregulation in human disease. Nucleic Acids
Res. 37:D98–D104. 2009. View Article : Google Scholar :
|
|
26
|
Xiao F, Zuo Z, Cai G, Kang S, Gao X and Li
T: miRecords: An integrated resource for microRNA-target
interactions. Nucleic Acids Res. 37:D105–D110. 2009. View Article : Google Scholar
|
|
27
|
Naeem H, Küffner R, Csaba G and Zimmer R:
miRSel: Automated extraction of associations between microRNAs and
genes from the biomedical literature. BMC Bioinformatics.
11:1352010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Law V, Knox C, Djoumbou Y, Jewison T, Guo
AC, Liu Y, Maciejewski A, Arndt D, Wilson M, Neveu V, et al:
DrugBank 4.0: Shedding new light on drug metabolism. Nucleic Acids
Res. 42:D1091–D1097. 2014. View Article : Google Scholar :
|
|
29
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for Annotation,
Visualization, and Integrated Discovery. Genome Biol. 4:32003.
View Article : Google Scholar
|
|
30
|
Smoot ME, Ono K, Ruscheinski J, Wang PL
and Ideker T: Cytoscape 2.8: New features for data integration and
network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar :
|
|
31
|
Jebb A, Hadden P and Broom RJ: Uveal
metastasis and myasthenia gravis in a patient with recurrent renal
cell carcinoma treated with pazopanib. Clin Genitourin Cancer.
12:e143–e146. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Williams AE, Perry MM, Moschos SA,
Larner-Svensson HM and Lindsay MA: Role of miRNA-146a in the
regulation of the innate immune response and cancer. Biochem Soc
Trans. 36:1211–1215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang J, Jia G, Liu Q, Hu J, Yan M, Yang
B, Yang H, Zhou W and Li J: Silencing miR-146a influences B cells
and ameliorates experimental autoimmune myasthenia gravis.
Immunology. 144:56–67. 2015. View Article : Google Scholar
|
|
34
|
Arimori S and Song ZJ: Expression of
c-myc, c-Ki-ras and c-Ha-ras oncogene products in peripheral blood
mononuclear cells from patients with myasthenia gravis. Intern Med.
32:519–522. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Aznar S and Lacal JC: Searching new
targets for anticancer drug design: The families of Ras and Rho
GTPases and their effectors. Prog Nucleic Acid Res Mol Biol.
67:193–234. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Palanichamy A, Jahn S, Nickles D, Derstine
M, Abounasr A, Hauser SL, Baranzini SE, Leppert D and von Büdingen
HC: Rituximab efficiently depletes increased CD20-expressing T
cells in multiple sclerosis patients. J Immunol. 193:580–586. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Díaz-Manera J, Martínez-Hernández E,
Querol L, Klooster R, Rojas-García R, Suárez-Calvet X, Muñoz-Blanco
JL, Mazia C, Straasheijm KR, Gallardo E, et al: Long-lasting
treatment effect of rituximab in MuSK myasthenia. Neurology.
78:189–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Stein B and Bird SJ: Rituximab in the
treatment of MuSK antibody-positive myasthenia gravis. J Clin
Neuromuscul Dis. 12:163–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lebrun C, Bourg V, Tieulie N and Thomas P:
Successful treatment of refractory generalized myasthenia gravis
with rituximab. Eur J Neurol. 16:246–250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Thomas A, Rajan A, Berman A, Tomita Y,
Brzezniak C, Lee MJ, Lee S, Ling A, Spittler AJ, Carter CA, et al:
Sunitinib in patients with chemotherapy-refractory thymoma and
thymic carcinoma: an open-label phase 2 trial. Lancet Oncol.
16:177–186. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Samuelsson A, Towers TL and Ravetch JV:
Anti-inflammatory activity of IVIG mediated through the inhibitory
Fc receptor. Science. 291:484–486. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Qiao J, Zhou G, Ding Y, Zhu D and Fang H:
Multiple paraneoplastic syndromes: Myasthenia gravis, vitiligo,
alopecia areata, and oral lichen planus associated with thymoma. J
Neurol Sci. 308:177–179. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Arroyo González R, Kita M, Crayton H,
Havrdova E, Margolin DH, Lake SL and Giovannoni G: CARE-MS I and II
Investigators: Alemtuzumab improves quality-of-life outcomes
compared with subcutaneous interferon beta-1a in patients with
active relapsing-remitting multiple sclerosis. Mult Scler. Nov
24–2016.Epub ahead of print. View Article : Google Scholar
|
|
44
|
Giovannoni G, Cohen JA, Coles AJ, Hartung
HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara
MA and Compston DA; CARE-MS II Investigators: Alemtuzumab improves
preexisting disability in active relapsing-remitting MS patients.
Neurology. 87:1985–1992. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lorenzi AR, Clarke AM, Wooldridge T,
Waldmann H, Hale G, Symmons D, Hazleman BL and Isaacs JD: Morbidity
and mortality in rheumatoid arthritis patients with prolonged
therapy-induced lymphopenia: twelve-year outcomes. Arthritis Rheum.
58:370–375. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Datta-Mitra A, Riar NK and Raychaudhuri
SP: Remission of psoriasis and psoriatic arthritis during
bevacizumab therapy for renal cell cancer. Indian J Dermatol.
59:6322014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Akman A, Yilmaz E, Mutlu H and Ozdogan M:
Complete remission of psoriasis following bevacizumab therapy for
colon cancer. Clin Exp Dermatol. 34:e202–e204. 2009. View Article : Google Scholar
|
|
48
|
MacMillan CJ, Furlong SJ, Doucette CD,
Chen PL, Hoskin DW and Easton AS: Bevacizumab diminishes
experimental autoimmune encephalomyelitis by inhibiting spinal cord
angiogenesis and reducing peripheral T-cell responses. J
Neuropathol Exp Neurol. 71:983–999. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sullivan T, Benjamin CG, Kempf PW and
Deeken JF: Cetuximab in the treatment of rheumatoid arthritis. J
Clin Rheumatol. 16:32–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dawood S, Gong Y, Broglio K, Buchholz TA,
Woodward W, Lucci A, Valero V, Gonzalez-Angulo AM, Hortobagyi GN
and Cristofanilli M: Trastuzumab in primary inflammatory breast
cancer (IBC): High pathological response rates and improved
outcome. Breast J. 16:529–532. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lotti T, Chimenti S, Katsambas A, Ortonne
JP, Dubertret L, Licu D and Simon J: Efficacy and safety of
efalizumab in patients with moderate-to-severe plaque psoriasis
resistant to previous anti-psoriatic treatment: Results of a
multicentre, open-label, phase IIIb/IV trial. Arch Drug Inf.
3:9–18. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
James DG, Seo DH, Chen J, Vemulapalli C
and Stone CD: Efalizumab, a human monoclonal anti-CD11a antibody,
in the treatment of moderate to severe Crohn's disease: an
open-label pilot study. Dig Dis Sci. 56:1806–1810. 2011. View Article : Google Scholar
|
|
53
|
Polonsky W, Traylor L, Gao L, Wei W, Ameer
B, Stuhr A and Vlajnic A: Improved treatment satisfaction in
patients with type 1 diabetes treated with insulin glargine 100U/mL
versus neutral protamine Hagedorn insulin: An exploration of key
predictors from two randomized controlled trials. J Diabetes
Complications. Dec 8–2016.Epub ahead of print.
|
|
54
|
Cowan AJ, Laszlo GS, Estey EH and Walter
RB: Antibody-based therapy of acute myeloid leukemia with
gemtuzumab ozogamicin. Front Biosci (Landmark Ed). 18:1311–1334.
2013. View Article : Google Scholar
|
|
55
|
Creed TJ, Probert CS, Norman MN, Moorghen
M, Shepherd NA, Hearing SD and Dayan CM; BASBUC INVESTIGATORS:
Basiliximab for the treatment of steroid-resistant ulcerative
colitis: further experience in moderate and severe disease. Aliment
Pharmacol Ther. 23:1435–1442. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Piedimonte G, King KA, Holmgren L,
Bertrand PJ, Rodriguez MM and Hirsch RL: A humanized monoclonal
antibody against respiratory syncytial virus (palivizumab) inhibits
RSV-induced neurogenic-mediated inflammation in rat airways.
Pediatr Res. 47:351–356. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ueda D, Hori T, Nguyen JH and Uemoto S:
Muromonab-CD3 therapy for refractory rejections after liver
transplantation: a single-center experience during two decades in
Japan. J Hepatobiliary Pancreat Sci. 17:885–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Kereiakes DJ: Inflammation as a
therapeutic target: a unique role for abciximab. Am Heart J.
146(Suppl 4): S1–S4. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Jacene H, Crandall J, Kasamon YL, Ambinder
RF, Piantadosi S, Serena D, Kasecamp W and Wahl RL: Initial
experience with tositumomab and I-131-labeled tositumomab for
treatment of relapsed/refractory Hodgkin lymphoma. Mol Imaging
Biol. Oct 31–2016.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Arnason JE, Luptakova K, Rosenblatt J,
Tzachanis D, Avigan D, Zwicker JI, Levine J, Kim M, Parker JA,
Grant B and Joyce RM: Yttrium-90 ibritumomab tiuxetan followed by
rituximab maintenance as treatment for patients with diffuse large
B-cell lymphoma are not candidates for autologous stem cell
transplant. Acta Haematol. 133:347–353. 2015. View Article : Google Scholar : PubMed/NCBI
|
